Objective: To ascertain the effect of inhaled corticosteroid use on gain in height and weight of asthmatic pediatric outpatients.
Introduction
Inhaled corticoids (IC) have been used with success 1 for more than 2 decades for the prevention of persistent moderate and severe asthma, 2 reducing hospital admissions, visits to emergency services, oral corticoid (OC) bronchodilator usage and frequency of symptoms. 1 Nevertheless, adverse effects linked to their use have been described, dependent on dose, length of treatment, method of administration and mode of withdrawal abrupt or gradual. 2, 3 All chronic diseases, including asthma, can affect growth. 4, 5 A review article 4 listed early onset of asthma, disease severity, hypoxemia, chronic anorexia, corticoid use and low socioeconomic status as possible factors responsible for growth restriction.
Several different studies have been conducted to investigate the effect of IC on growth. 6 One of these 7 found short stature in children with asthma and rhinitis was associated with birth weight below 2,500 g and prolonged disease duration rather than with corticoid use; others have found links between growth restriction and OC use, 8 type of IC, method of administration (during the first year of use) 9 and high doses 10 of IC.
Possible risk factors for restricted height in children considered normal that have been described include: low maternal educational level, per capita income less than or equal to 0.5 national minimum wages, short maternal and paternal stature and short stature and low weight at birth. [11] [12] [13] [14] The objective of this study was to investigate the possibility that IC influences the height and weight gain of asthmatic children in chronic treatment at two clinics on the public health system in Porto Alegre (Rio Grande do Sul state) that provide medication free of charge.
Patients and methods
This was a prospective cohort study. The object of the study was the effect of the use of IC in asthmatic children and adolescents and outcomes were height and weight Vargas or the Posto IAPI, both part of the municipal health system of Porto Alegre. Children aged less than 9 years had been prescribed IC for at least 1 year and those aged 9 or more for at least 2 years. Patients were excluded if their birth weights had been < 2,500 g, they were malnourished (weight/age index < -2 z-scores), had other chronic diseases or were on continuous OC. The medical records of patients enrolled were reviewed from the date they had registered at the clinic and the following details recorded: initial height and weight, the IC prescribed, nasal corticoid (NC) usage, dose, duration of use, the use of other drugs and the number and severity of asthma crises. On enrollment one guardian of each patient was interviewed for collection of social data (income, parents education and living conditions) and clinical data (number of asthma crises, previous hospitalizations, visits to emergency, diseases and, at every follow-up appointment, corticoid use and dosage). Children consulted at intervals of 1 to 3 months. Questionnaires were filled out by three previously trained interviewers in order to maintain uniformity of information. Puberty was evaluated using the Tanner classification. 15 Compliance with treatment was assessed by verification of the number of corticoid vials used. Every child enrolled on the study had their height measured barefoot, standing erect against a flat vertical surface with heels together, using the same stadiometer (brand Seca, wall mounted, with precision to 0. When z-scores for height (HAZ) and weight (WAZ) were calculated, short stature was defined as HAZ < -2, overweight as body mass index (BMI) z-score from +1 to +2, obesity as BMI z-score > +2. Body mass indices [weight (kg)/height (m 2 )] were also compared with the NCHS curves, taking account of age and sex of participants.
Mid-parental target heights were also calculated for all participants. This represents the height that 95% of the children of a couple should attain in adulthood. 17, 18 The following formulae were used to calculate mid-parental targets:
Girls:
Mothers height + (fathers height -13 cm) This target was used to find the point on the NCHS curves that corresponded to the current age of the patient on the percentile of their target height. Parents heights were determined using the same stadiometer described above or, in the cases of 38 fathers and two mothers, from the mean of three measurements taken at home by the parent who attended the consultations and who had been trained to measure the parent who did not attend.
Children were defined as having poorly-controlled asthma if they presented two or more crises requiring OC during the study year, if they had to attend emergency or if they required hospital admission. 19 Nasal and IC were doses. The mean daily use for the year was calculated from these data.
Ethical considerations
The study protocol was approved by the Research Ethics Committee at the Hospital Presidente Vargas, and permission was received from the Posto IAPI. The study was considered of minimal risk and informed consent was given by parents or guardians (98.6% agreed).
Statistical analysis
The sample size was estimated at 73 children based on a calculation designed to allow the detection of a 1 cm difference in mean height, with standard difference deviation of 3 cm, alpha of 0.05 and power of 80%. between parental target height adjusted for current age (PHAA) and HAZ was assessed using Pearsons correlation coefficient. The level of significance adopted was 5%, and analysis was performed using SPSS version 10.0.
Results
One hundred and forty patients took part in the study.
One hundred and twenty four of these were followed for 1 year (88.5%). Patients were defined as lost to the study if it was not possible to measure their height after 1 year of follow-up, because they did not attend return appointments (15 cases) and children who were not compliant with treatment, identified by the fact that fresh IC supplies were not required on more than one occasion (one case). There were, therefore, 16 losses, in 15 of these cases it was possible to contact the family by telephone and non-attendance was explained by the disappearance of symptoms.
The mean age of the 124 cases that were followedup for 1 year was 8.6 years and 81 children were less than 10 years old. The majority of the children were from low-income families and mean maternal schooling was 6.9 years. There were 74 boys, 59 children were pubescent in 77 cases asthma was well controlled. mg/cycle. Overall, 70.9% of the children were given the equivalent of up to 600 mg/day of beclomethasone, and 29.1% were given the equivalent of more than 600 µg/day. These and other characteristics are presented in Table 1 . Mean ± SD for the time between first consultation at the asthma clinic and enrollment on the study was 31.43±20.51 months.
Once the figures for overall patient height on the date of the first consultation within the study period were assessed, it was observed that mean height was greater than the mean adjusted target parental height (p < 0.001) and was similar to the 50th percentile of the NCHS curve ( Table 2 ). Analysis of HAZ returned a mean figure of 0.04±1.14 for date of registration at the clinic, similar to the 0.06±1.20 for the date of the first visit during the study period (p = 0.800).
Mean overall height and BMI gain during the year were When the sample was broken down into groups pubescent vs. prepubescent, controlled vs. uncontrolled asthma and male vs. female sex, there were also no significant difference in height gain (data not shown).
Overall BMI for the patients on the date of their first visit within the study (mean ± SD) was 18.2±3.16 (Table   3 ) and, 1 year later it was 18.7±3. Hospital admission during year prior to first consultation 0.23±1.4 0 1
Length of time on treatment prior to study (in months) 31.43±20.51 7 105 Table 1 -Baseline characteristics on enrollment BMI = body mass index; HAZ = height/age z-score; P = percentile; SD = standard deviation; WAZ = weight/age z-score. HAZ = height/age z-score; P = percentile; SD = standard deviation; ∆ = difference.
* Using Student's t test for paired samples, here was statistically significant difference between actual height and parental target height at the same point (initial vs. initial, final vs. final), p < 0.001. † There was a significant difference between final and initial values, p < 0.001, but there were no significant differences in distribution by z-score < -2 (p = 0.500) or z < -1 (p = 0.219) from enrollment (initial value) to the 1 year follow-up (final value). * There was a significant difference between the final and initial values p < 0.001, but there were no significant differences in distribution BMI z-score after 1 year (p = 0.424). the end of the study, and neither did the mean ± SD of WAZ differ significantly (initial WAZ = 0.6±1.5; final WAZ = 0.5±1.5; 95%CI 1.84-6.6; p = 0.808).
When patients were split into groups according to the type of inhaled corticoid, it was observed that the mean BMI for patients in different groups was similar at enrollment 
Discussion
Research into the growth of asthmatics using corticoid therapy has returned conflicting results. 4, 10, 20, 21 Intervention studies, such as randomized clinical trials, are the most appropriate form of study for assessing cause and effect. However, in the case of asthma such studies have ethical limitations since there is no question of the benefits of IC. 4 In the current study 124 patients who used IC were shown reduced height gain related to severity of asthma. 21 According to Luo et al., 25 95% of the population reach an adult height that is within 9-10 cm above or below the height predicted from their parents heights (mid-parental target height). When data from the current study was analyzed, comparing the heights of the children and adolescents with their parental target heights, it was observed that the IC had not provoked growth restriction, which is in agreement with a study by Agertoft & Pedersen. 20 On the other hand, both at the first visit and at 1 year follow-up, the mean heights of the children participating in this study were above those predicted from their parental target heights, in accordance with a tendency that has been reported for many populations worldwide and which, apparently, reflects the improved socioeconomic conditions of these populations when compared with those of their parents, just one generation earlier. 26, 27 Therefore, it can be stated that there is no compromise to the height of the children studied after more than 1 year of IC use.
On the contrary, these children are following the tendency to reach an average height above that of their parents and to grow in line with their genetic potential (when the possibility of a correlation between HAZ and height of parents was evaluated it was observed that there was a positive correlation).
It is of interest to note that, in the current study, patients using beclomethasone powder exhibited a reduced height gain over 1 year. It should be emphasized that this project was not designed to detect the effects of different types of corticoids and the sample size was not calculated with this objective in mind. Other studies have observed that IC in powder has an influence on growth. 9, 28 While the sample size of this study was small with respect of the different types of IC, the findings exhibit a tendency that is similar to the studies cited above. The oral bioavailability, systemic absorption and hepatic metabolism of IC in powder contributes to a potential systemic effect. 29 Taking into account the fact that IC are offered in preparations with varying bioavailability, it should be possible to detect differences in growth provoked by doses with similar anti-inflammatory power given to children, but with differences in the form of presentation (for example, in powder or aerosol). 30 The fact that different doses and formulations of IC were employed, creating the need to find a measure of equivalence, is a limitation to the current study. Nevertheless, in published literature the same type of estimate has been used and the results are comparable, particularly in the cases of the most-used drugs such as budesonide and beclomethasone. 29 While the primary objective of the current study was not to evaluate the effect of IC on BMI either, in contrast with other authors, 31 no significant increase in WAZ was observed after 1 year, suggesting that the systemic effects of IC are not important.
Conclusions
This follow-up study of asthmatic children on IC, did not demonstrate any compromise to height gain after 1 year of observation, but actually detected mean growth above what would be expected based on mid-parental targets. This tendency has been described for normal children living in first world countries. The observed heights reinforce the idea that the negative influence of treatment with IC on final height is absent, although, in order to confirm this these patients must be followed for a longer period, i.e. until adulthood. The observation of similar weight/age at the 1 year follow-up appointment also suggests little or no systemic effect related to IC use.
On the other hand, it is impossible to rule out the possibility that compliance with treatment was not adequate. Furthermore, in the current study a tendency was observed towards reduced growth with beclomethasone powder. Further studies of this particular IC presentation are necessary to confirm this tendency.
